- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Peter Beitsch, MD | Authors
Articles
Dr. Peter Beitsch on the Benefits of Grouping Patients With Breast Cancer by Subtype for Trials
February 16, 2016
Video
Beitsch says that while having a study that incorporates several thousands of patients will potentially produce statistically significant results, these larger groups may not account for subtypes in each patient's individual cancer.
Dr. Peter Beitsch on Pertuzumab in the Luminal Subtype of HER2-Positive Breast Cancer
December 22, 2015
Video
Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings.